FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022773701> ?p ?o ?g. }

• W2022773701 abstract "Introduction: Type 2 diabetes mellitus (T2DM) is a complex disease with a number of metabolic abnormalities. At present, treatment typically proceeds in a stepwise fashion, beginning with diet and exercise followed by incremental additions of oral antidiabetic agents as required to achieve and maintain glycemic control (glycosylated hemoglobin [HbA1c] ≤6.9% and 6.5%, respectively). This approach is reactive rather than proactive as progression to the next level is based on treatment failure (i.e., not achieving target HbA1c levels). Newer approaches to treatment of T2DM advocate early use of combination antihyperglycemic regimens with complementary mechanisms of action to correct multiple pathophysiologic defects, but this can impact negatively on treatment adherence. Fixed-dose combinations are associated with higher compliance rates than therapy with individual components administered concomitantly. This review examines evidence for a fixed-dose combination of alogliptin and pioglitazone recently approved for use in Japanese patients with T2DM. Methods: A MEDLINE search identified five randomized, controlled trials in which alogliptin and pioglitazone were used in combination to treat T2DM, and these form the basis of the review. Results: One study evaluated alogliptin-pioglitazone combination therapy in drug-naïve patients. In the remaining studies, alogliptin was evaluated as add-on therapy in patients with inadequate glycemic control despite treatment with pioglitazone (± metformin or sulfonylurea). In all studies, alogliptin-pioglitazone combination therapy consistently produced statistically significant reductions in HbA1c of approximately 0.6–1.0% over and above those produced by either agent alone. This improvement was paralleled by improvements in fasting plasma glucose, proportions of patients achieving target HbA1c levels and several other measures of glycemic control, including markers of beta-cell function. The alogliptin-pioglitazone combination was well tolerated across all studies. Conclusion: Alogliptin-pioglitazone combination therapy represents a rational approach to treatment of T2DM as the complementary mechanisms target several aspects of impaired glucose control. The fixed-dose combination offers scope for enhanced patient compliance and improved treatment outcomes." @default.
• W2022773701 created "2016-06-24" @default.
• W2022773701 creator A5010302035 @default.
• W2022773701 creator A5036190568 @default.
• W2022773701 creator A5059373121 @default.
• W2022773701 date "2012-01-01" @default.
• W2022773701 modified "2023-09-25" @default.
• W2022773701 title "Alogliptin-Pioglitazone Combination Therapy: A Rational Approach to Treating Type 2 Diabetes Mellitus" @default.
• W2022773701 cites W1551046670 @default.
• W2022773701 cites W1566255677 @default.
• W2022773701 cites W1584240097 @default.
• W2022773701 cites W1951261947 @default.
• W2022773701 cites W1983216490 @default.
• W2022773701 cites W1986550531 @default.
• W2022773701 cites W1992868203 @default.
• W2022773701 cites W1997416444 @default.
• W2022773701 cites W2027788348 @default.
• W2022773701 cites W2031125972 @default.
• W2022773701 cites W2037455506 @default.
• W2022773701 cites W2043269192 @default.
• W2022773701 cites W2046381181 @default.
• W2022773701 cites W2047277644 @default.
• W2022773701 cites W2059764669 @default.
• W2022773701 cites W2064617441 @default.
• W2022773701 cites W2066734164 @default.
• W2022773701 cites W2066929611 @default.
• W2022773701 cites W2068605328 @default.
• W2022773701 cites W2071090755 @default.
• W2022773701 cites W2073841569 @default.
• W2022773701 cites W2075646098 @default.
• W2022773701 cites W2078923086 @default.
• W2022773701 cites W2082354988 @default.
• W2022773701 cites W2086842286 @default.
• W2022773701 cites W2092583867 @default.
• W2022773701 cites W2092918268 @default.
• W2022773701 cites W2093356629 @default.
• W2022773701 cites W2104288577 @default.
• W2022773701 cites W2109728760 @default.
• W2022773701 cites W2112220590 @default.
• W2022773701 cites W2113297547 @default.
• W2022773701 cites W2121970519 @default.
• W2022773701 cites W2127608460 @default.
• W2022773701 cites W2128648250 @default.
• W2022773701 cites W2129811887 @default.
• W2022773701 cites W2136225651 @default.
• W2022773701 cites W2142336725 @default.
• W2022773701 cites W2145335273 @default.
• W2022773701 cites W2148382332 @default.
• W2022773701 cites W2151668968 @default.
• W2022773701 cites W2163498104 @default.
• W2022773701 cites W2164733897 @default.
• W2022773701 cites W4240449862 @default.
• W2022773701 cites W8868324 @default.
• W2022773701 doi "https://doi.org/10.1007/s13556-012-0004-0" @default.
• W2022773701 hasPublicationYear "2012" @default.
• W2022773701 type Work @default.
• W2022773701 sameAs 2022773701 @default.
• W2022773701 citedByCount "2" @default.
• W2022773701 countsByYear W20227737012015 @default.
• W2022773701 countsByYear W20227737012017 @default.
• W2022773701 crossrefType "journal-article" @default.
• W2022773701 hasAuthorship W2022773701A5010302035 @default.
• W2022773701 hasAuthorship W2022773701A5036190568 @default.
• W2022773701 hasAuthorship W2022773701A5059373121 @default.
• W2022773701 hasBestOaLocation W20227737011 @default.
• W2022773701 hasConcept C126322002 @default.
• W2022773701 hasConcept C134018914 @default.
• W2022773701 hasConcept C168563851 @default.
• W2022773701 hasConcept C2776999253 @default.
• W2022773701 hasConcept C2777180221 @default.
• W2022773701 hasConcept C2778384471 @default.
• W2022773701 hasConcept C2779284873 @default.
• W2022773701 hasConcept C2780012697 @default.
• W2022773701 hasConcept C2780323712 @default.
• W2022773701 hasConcept C2780473172 @default.
• W2022773701 hasConcept C2910068830 @default.
• W2022773701 hasConcept C555293320 @default.
• W2022773701 hasConcept C71924100 @default.
• W2022773701 hasConcept C98274493 @default.
• W2022773701 hasConceptScore W2022773701C126322002 @default.
• W2022773701 hasConceptScore W2022773701C134018914 @default.
• W2022773701 hasConceptScore W2022773701C168563851 @default.
• W2022773701 hasConceptScore W2022773701C2776999253 @default.
• W2022773701 hasConceptScore W2022773701C2777180221 @default.
• W2022773701 hasConceptScore W2022773701C2778384471 @default.
• W2022773701 hasConceptScore W2022773701C2779284873 @default.
• W2022773701 hasConceptScore W2022773701C2780012697 @default.
• W2022773701 hasConceptScore W2022773701C2780323712 @default.
• W2022773701 hasConceptScore W2022773701C2780473172 @default.
• W2022773701 hasConceptScore W2022773701C2910068830 @default.
• W2022773701 hasConceptScore W2022773701C555293320 @default.
• W2022773701 hasConceptScore W2022773701C71924100 @default.
• W2022773701 hasConceptScore W2022773701C98274493 @default.
• W2022773701 hasIssue "1" @default.
• W2022773701 hasLocation W20227737011 @default.
• W2022773701 hasOpenAccess W2022773701 @default.
• W2022773701 hasPrimaryLocation W20227737011 @default.
• W2022773701 hasRelatedWork W2027788348 @default.
• W2022773701 hasRelatedWork W2070740840 @default.
• W2022773701 hasRelatedWork W2104288577 @default.

• next